MétaCan
Menu
Back to cohort
Record W2904773293 · doi:10.1111/ajt.15214

The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium’s position statement

2018· article· en· W2904773293 on OpenAlexfundno aff
Mark D. Stegall, Kenneth Troy Somerville, Matthew J. Everly, Roslyn B. Mannon, A. Osama Gaber, M. Roy First, Neetu Agashivala, Vanessa Pérez, Kenneth A. Newell, Randall E. Morris, Debra L. Sudan, Klaus Romero, Sonya Eremenco, Maria Mattera, Nicole Spear, Amy C. Porter, Inish O’Doherty

Bibliographic record

VenueAmerican Journal of Transplantation · 2018
Typearticle
Languageen
FieldMedicine
TopicRenal Transplantation Outcomes and Treatments
Canadian institutionsnot available
FundersTransplantation SocietyCareDxAmerican Society of Transplant SurgeonsBristol-Myers SquibbShireCSL BehringNational Institute of Diabetes and Digestive and Kidney DiseasesAmerican Society of TransplantationSanofiNovartisAstellas Pharma USU.S. Food and Drug Administration
KeywordsMedicineTolerabilityPosition statementIntensive care medicineSafety profileImmunosuppressionDrugRenal transplantImmunosuppressive drugAdverse effectPharmacologyTransplantationInternal medicineFamily medicine

Abstract

fetched live from OpenAlex

The Transplant Therapeutics Consortium (TTC) is a public-private partnership between the US Food and Drug Administration and the transplantation community including the transplantation societies and members of the biopharmaceutical industry. The TTC was formed to accelerate the process of developing new medical products for transplant patients. The initial goals of this collaboration are the following: (a) To define which aspects of the kidney transplant drug-development process have clear needs for improvement from an industry and regulatory perspective; (b) to define which of the unmet needs in the process could be positively impacted through the development of specific drug-development tools based on available data; and (c) to determine the most appropriate pathway to achieve regulatory acceptance of the proposed process-accelerating tools. The TTC has identified 2 major areas of emphasis: new biomarkers or endpoints for determining the efficacy of new therapies and new tools to assess the safety or tolerability of new therapies. This article presents the rationale and planned approach to develop new tools to assess safety and tolerability of therapies for transplant patients. We also discuss how similar efforts might support the continued development of patient-reported outcome measures in the future.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.170
metaresearch head score (Gemma)0.142
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.170
Threshold uncertainty score0.897

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1700.142
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0020.003
Science and technology studies0.0050.014
Scholarly communication0.0200.012
Open science0.0060.008
Research integrity0.0420.057
Insufficient payload (model declined to judge)0.0020.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.323
Teacher spread0.300 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations20
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueAmerican Journal of TransplantationSame topicRenal Transplantation Outcomes and TreatmentsFrench-language works237,207